Optimist, your actions sound like they are organized around the fate of Praulent, ignoring that Regeneron has two other potentially huge drug markets besides Eylea. You are probably making a good short term call if the drug is pulled but many of us are long Regeneron and will make considerably more money than you will.
Also, why don't you dial down the hostility and increase the level of content in your conversation about the company. You sound like your at a Trump rally.
I think that you both have good points. I think that in the short term it goes down in relationship to Praluent legal stuff. The news though over the next three or four months should be good and so I think it slowly goes up in relationship to eczema drug. My biggest concern is that the rotation back to biotech doesn't happen until after the election. Even though Congress understands that research costs money and that smart, ethical companies like Regeneron are not price gaugers, still the market reacts very negatively to any politician who mentions the price of drugs. Unfortunately, a few very bad examples of unethical behavior scare investors.
I agree entirely with what you say long term but I think that it will go down 20-30 in response to this ER. I don't know where the trigger will be for the massive institutional selling that has been going on since January to reverse and have them start buying Regeneron again.